[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastroparesis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastroparesis":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,36,0,25,[9,55,81,107,138,160,179,203,231,260,281,300,337,363,388,414,432,454,481,504,527,558,583,606,627],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":34,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100401388","indiana-university-gastrointestinal-motility-diagnosis-registry-100401388",false,"NCT04506593","Indiana University Gastrointestinal Motility Diagnosis Registry","Gastrointestinal Motility Diagnosis Registry","Inclusion Criteria:\n\n1. Patients who presented to the GI outpatient clinics, in-patient consult service, and outpatient endoscopy centers within the Division of Gastroenterology and Hepatology\n2. Carries a diagnosis of GI motility disorder based on the diagnostic criteria listed in table\n\nExclusion Criteria:\n\n1\\. Coexisting medical conditions that may limiting participation in clinical research trial","ALL",{"count":19,"type":20},5000,"ESTIMATED","10 Years","OBSERVATIONAL","Develop a registry (list of patients) with accurate clinical motility diagnosis. This registry will help the doctors to identify the patients with specific disease conditions. It will also help in promoting future research in gastroenterology motility disorders",[25,26,27,28,29,30,31,32,33],"Eosinophilic Esophagitis","Gastroesophageal Reflux Disease (GERD)","Gastroparesis","Functional Vomiting","Irritable Bowel Syndrome (IBS)","Constipation","Chronic Intestinal Pseudo-obstruction","Fecal Incontinence","Small Intestinal Bacterial Overgrowth",[35,36,37,38,39,40,41,27],"Eosinophilic esophagitis","Chronic intestinal pseudo-obstruction","Small Bowel dysmotility","SIBO","Vomiting","Functional dyspepsia","Functional bloating","RECRUITING","2026-06-15",{"date":45,"type":46},"2026-06-16","ACTUAL",{"date":48,"type":46},"2014-11-01",{"date":50,"type":20},"2026-11",{"name":52,"class":53},"Indiana University","OTHER",1,{"id":56,"slug":57,"hasResults":12,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":4,"eligibilityCriteria":61,"healthyVolunteers":62,"sex":17,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":67,"studyType":22,"phases":4,"briefSummary":68,"conditions":69,"keywords":70,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":75,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":54},"100221816","gi-neuromuscular-pathology-prospective-registry-100221816","NCT02165059","GI Neuromuscular Pathology Prospective Registry","Indiana University GI Neuromuscular Pathology Prospective Registry","Inclusion Criteria Study Group:\n\nPatients who are undergoing surgical full-thickness biopsy of the stomach and\u002For proximal jejunum for the clinical evaluation of GI neuromuscular disorder.\n\nInclusion Criteria Control Group:\n\nPatients undergoing esophagectomy, sleeve gastrectomy for obesity, or Roux-en Y gastric bypass Patients undergoing Whipple surgery Patients undergoing transplant surgery\n\nPatients who are organ donors and undergoing surgery\n\nExclusion Criteria Study Group:\n\nContraindication for surgical full-thickness biopsy for any reason. Significant comorbidity due to severe cardiovascular, renal, pulmonary, or liver disease.\n\nSignificant coagulopathy Non-ambulatory patients: bed-ridden, nursing home resident. Pregnant Unable to give own informed consent Prisoners\n\nExclusion Criteria Control Group:\n\nPrior diagnosis of gastroparesis Prior diagnosis of chronic intestinal pseudo-obstruction Unable to give own informed consent if not an organ donor",true,"6 Months","90 Years",{"count":66,"type":20},300,"2 Years","In this research study, biopsy samples will be collected to provide more insight into the underlying cause of the motility disorders, help direct further investigation into the cause of the underlying condition, provide future prognosis and predict response to gastric electrical stimulation (GES).",[27],[71,39,40,72,73,74],"Nausea","Bloating","Regurgitation","Retching",{"date":45,"type":46},{"date":77,"type":46},"2013-12-01",{"date":79,"type":20},"2026-12",{"name":52,"class":53},{"id":82,"slug":83,"hasResults":12,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":12,"sex":17,"minAge":88,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":106},"100581731","prokinetics-and-body-surface-gastric-mapping-in-dyspeptic-patients-baseline-and-treatment-effects-100581731","NCT06854120","Prokinetics and Body Surface Gastric Mapping in Dyspeptic Patients: Baseline and Treatment Effects","Body Surface Gastric Mapping in Patients With Dyspeptic Symptoms: Recordings at Baseline and on Medical Therapy","Inclusion Criteria:\n\n* Patients 18 years of age and older\n* Diagnosis of gastroparesis and\u002For functional dyspepsia\n* Being prescribed a prokinetic agent or symptom modulator for their clinical care\n* Able to undergo BSGM recording both before and during treatment\n* Able to give informed consent for undergoing a baseline BSGM recording and an additional recording while on treatment\n\nExclusion Criteria:\n\n* Under 18 years of age\n* Prior surgery on esophagus, stomach (appendectomy and cholecystectomy are allowed)\n* History of skin allergies or a history of extreme sensitivity to cosmetics or lotions\n* Pregnant women\n* No vulnerable groups such as prisoners, individuals with known cognitive impairment, or institutionalized individuals be involved","18 Years",{"count":90,"type":20},125,"Functional dyspepsia and gastroparesis are common stomach disorders with symptoms like early satiety, nausea, and abdominal pain, and are often evaluated with gastric emptying tests, although the correlation with symptoms is weak. Prokinetic agents (e.g., metoclopramide, erythromycin) and symptom modulators (e.g., nortriptyline, mirtazapine) are commonly used, but selecting the right medication can be difficult, as it's often based on symptoms rather than the underlying gastric issues. Body Surface Gastric Mapping (BSGM) using the Gastric Alimetry device is a novel, non-invasive tool to assess gastric myoelectrical activity and symptoms. This study aims to perform two BSGM recordings-one before and one after medical therapy-to understand how medications affect gastric function and identify baseline BSGM factors that could predict responses to treatment, potentially guiding tailored therapies based on individual gastric dysfunction.",[27,93],"Functional Dyspepsia",[27,93,95,96],"Gastric Motility","Body Surface Gastric Mapping","2026-06-08",{"date":99,"type":46},"2026-06-11",{"date":101,"type":46},"2025-02-26",{"date":103,"type":20},"2028-08-26",{"name":105,"class":53},"University of Auckland, New Zealand",3,{"id":108,"slug":109,"hasResults":12,"nctId":110,"briefTitle":111,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":12,"sex":17,"minAge":88,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":116,"phases":117,"briefSummary":119,"conditions":120,"keywords":122,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":54},"100635711","gastric-electrical-stimulation-for-abdominal-pain-in-patients-with-gastroparesis-100635711","NCT07556237","Gastric Electrical Stimulation for Abdominal Pain in Patients With Gastroparesis","HEAL","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Diagnosed gastroparesis.\n* Implanted Enterra™ device for at least 8 weeks prior to enrollment.\n* Chronic daily abdominal pain of gastric origin lasting more than 2 months.\n* Average pain score ≥4 on a 0-10 scale.\n* Ability to provide informed consent.\n\nExclusion Criteria:\n\n* Daily opioid use.\n* Pregnancy or breastfeeding.\n* Abdominal pain not attributed to gastric\u002Fvisceral origin.\n* Severe constipation or uncontrolled diabetes (HbA1c \\>10).\n* Other medical conditions that would interfere with study participation.",{"count":115,"type":20},150,"INTERVENTIONAL",[118],"NA","Gastroparesis is a disorder characterized by delayed gastric emptying and symptoms including nausea, vomiting, and abdominal pain. Gastric electrical stimulation (GES) using the implanted Enterra™ neurostimulator is FDA-approved to treat nausea and vomiting but its impact on abdominal pain has not been well studied. This study evaluates whether alternative programming parameters of the Enterra™ device can reduce abdominal pain in patients with gastroparesis. Participants with an existing Enterra™ device will be randomized to one of three stimulation settings and followed for assessment of pain, gastrointestinal symptoms, quality of life, and medication use.",[27,121],"Chronic Abdominal Pain",[123,124,125,126,127],"Gastric Electrical Stimulation","Enterra","Visceral pain","Gastroparesis pain","Neuromodulation","NOT_YET_RECRUITING","2026-04-28",{"date":131,"type":46},"2026-05-04",{"date":133,"type":20},"2026-07",{"date":135,"type":20},"2030-07",{"name":137,"class":53},"University of Louisville",{"id":139,"slug":140,"hasResults":12,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":144,"eligibilityCriteria":145,"healthyVolunteers":12,"sex":17,"minAge":88,"maxAge":146,"enrollmentInfo":147,"targetDuration":4,"studyType":116,"phases":149,"briefSummary":150,"conditions":151,"keywords":4,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":54},"100576300","effect-of-percutaneous-electrical-nerve-field-stimulation-on-symptom-controlnervous-system-activity-in-patients-wdiabetes-types-12-100576300","NCT06783504","Effect Of Percutaneous Electrical Nerve Field Stimulation on Symptom Control\u002FNervous System Activity in Patients w\u002FDiabetes Types 1\u002F2","Effect Of Percutaneous Electrical Nerve Field Stimulation (PENFS) On Symptom Control And Autonomic Nervous System Activity In Patients With Diabetes Mellitus","PENFS","Inclusion Criteria:\n\n* Wiling to have one teaspoon (5 ml) of blood drawn.\n* Diagnosed with gastroparesis for twelve months or longer\n* Diagnosed with diabetes either Type 1 or Type 2\n* Documented delayed gastric emptying (\\>10% retention of the test meal at four hours) on a standardized scrambled-egg scintigraphy gastric emptying test performed in the last two years.\n* Upper GI endoscopy indicating no mechanical obstruction performed in the last five years.\n* Symptoms of nausea and vomiting consistent with clinical diagnosis of gastroparesis (as opposed to other causes of nausea and vomiting such as mechanical obstruction, acute viral illness, chemotherapy, psychogenic vomiting.\n* Documented Hb A1c within three months of screening or at the time of screening (\\\u003C=8.0)\n\nExclusion Criteria:\n\n* Unable to provide consent\n* Pregnant females\n* Medical records indicate intestinal pseudo-obstruction\n* Diagnosed with cardiac arrhythmia\n* History of prior gastric surgery\n* History of vagotomy\n* History of organ transplantation\n* History of seizures\n* Diagnosed with primary swallowing disorders\n* Subjects who are dependent on drugs like Marinol for their condition\n* Those diagnosed with psychogenic vomiting and not related to gastroparesis\n* Medically unstable subjects\n* Those at high surgical risk\n* Subjects taking narcotic analgesics daily.\n* Those with poorly controlled diabetes mellitus (Hgb A1c\\>8) within three months of screening or at the time of screening.\n* Subjects diagnosed with hemophilia, psoriasis vulgaris are excluded\n* Those having a cardiac pacemaker will be excluded from the study.","60 Years",{"count":148,"type":20},60,[118],"The purpose of this study is to find out if we can stimulate the vagus nerve. The vagus nerve is a largely internal nerve that controls many bodily functions, including stomach function. We hope that electrically stimulating the nerve around the external ear will also stimulate the internal vagus nerve. If it does, then we hope that this will help our treatment of patients with nausea and vomiting and disordered stomach function.",[152,27],"Diabetes",{"date":154,"type":46},"2026-04-29",{"date":156,"type":20},"2027-02-10",{"date":158,"type":20},"2029-08",{"name":52,"class":53},{"id":161,"slug":162,"hasResults":12,"nctId":163,"briefTitle":164,"officialTitle":164,"acronym":165,"eligibilityCriteria":166,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":169,"conditions":170,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":54},"100353008","gastroparesis-outcome-longitudinal-database-enrolled-numerically-100353008","NCT03876288","Gastroparesis Outcome Longitudinal Database Enrolled Numerically","GOLDEN","Inclusion:\n\n* Patients with the symptoms (Sx) of drug refractory gastroparesis\n* Disordered nutrition by standardized assessment\n* Ability to assess current symptom status\n* Ability to measure other medical conditions\n\nExclusion:\n\n* Anatomic obstruction of the GI Tract\n* Pregnancy\n* Inability of patient or guardian to sign informed consent, if needed\n* Psychiatric disorders precluding assessment and treatment of the patient's GI condition",{"count":168,"type":20},3000,"GOLDEN is a longitudinal database of patients with the symptoms (Sx) of gastroparesis (Gp) who were seen and recorded at the University of Louisville from 2012 and is ongoing. Patients are enrolled and followed by sequential numbers and may include legacy patients seen at other centers by some of the same team and who are reported as part of the series. Outcome relate to patients Sx, survival, quality of life and other measures as detailed below, over time. The study tracks patients regardless of treatment but specifically focuses on GI Neuromodulation (gastric electrical stimulation - GES), Immunotherapy (IVIG), and Pyloric therapies (pyloroplasty, endoscopic). If treatments were administered GOLDEN allows for examination and stratification of outcome by groups both at baseline and at follow up.",[27],"2026-04-17",{"date":173,"type":46},"2026-04-20",{"date":175,"type":46},"2013-01-01",{"date":177,"type":20},"2028-01-01",{"name":137,"class":53},{"id":180,"slug":181,"hasResults":12,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":4,"eligibilityCriteria":185,"healthyVolunteers":12,"sex":17,"minAge":88,"maxAge":186,"enrollmentInfo":187,"targetDuration":4,"studyType":116,"phases":189,"briefSummary":191,"conditions":192,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":202},"100577845","early-phase-1-growth-hormone-for-the-treatment-of-gastroparesis-100577845","NCT06803589","Growth Hormone for the Treatment of Gastroparesis","Low-dose Growth Hormone for the Treatment of Gastroparesis","Inclusion Criteria:\n\n* Symptoms \\> 6 months that have not responded satisfactorily to standard treatment.\n* For gastroparesis: Gastroparesis Cardinal Symptom Index (GCSI) score of \\>21\n\nExclusion Criteria:\n\n* Known history of GH deficiency, hypothalamic or pituitary disease\n* Diabetes\n* Prior use of GH therapy\n* Age-adjusted low serum IGF1\n* Women on oral estrogen therapy6\n* Pregnancy or nursing\n* History of malignant solid tumors\n* Obesity (BMI \\> 30)History of coronary and thromboembolic diseases.\n* History of sarcoidosis\n* History of pituitary surgery\n* History of thyroid nodules.\n* Any other condition, which in the opinion of the investigator would impede compliance or hinder completion of the study.\n* Failure to give informed consent.","65 Years",{"count":188,"type":20},10,[190],"EARLY_PHASE1","The purpose of this study is to determine whether treatment with Growth Hormone results in symptomatic improvement in patients with gastroparesis.",[27],"2026-04-13",{"date":195,"type":46},"2026-04-16",{"date":197,"type":46},"2024-10-22",{"date":199,"type":20},"2027-12",{"name":201,"class":53},"Mayo Clinic",2,{"id":204,"slug":205,"hasResults":12,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":4,"eligibilityCriteria":209,"healthyVolunteers":12,"sex":17,"minAge":210,"maxAge":4,"enrollmentInfo":211,"targetDuration":4,"studyType":116,"phases":213,"briefSummary":215,"conditions":216,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":54},"100185996","phase-3-domperidone-in-treating-patients-with-gastrointestinal-disorders-100185996","NCT01696734","Domperidone in Treating Patients With Gastrointestinal Disorders","Treatment Protocol for the Compassionate Use of Domperidone","Inclusion Criteria:\n\n* Patients with GI disorders who have failed standard therapy\n* Symptoms or manifestations of: a) gastroparesis; b) refractory gastroesophageal reflux disease (GERD) including persistent esophagitis, refractory heartburn, reflux-related laryngitis, and respiratory symptoms; or c) severe dyspepsia\n* Completion of a comprehensive evaluation, including clinical history and physical examination, to eliminate other causes of their symptoms\n* Patient has signed the informed consent document agreeing to the use of the study drug, domperidone\n* White blood cell (WBC) with differential greater than 3,000\u002Fml\n* Alkaline phosphatase less than 1.5 x upper limit of normal\n* Alanine aminotransferase (ALT) less than 2 x upper limit of normal\n* Aspartate aminotransferase (AST) less than 2 x upper limit of normal\n* Bilirubin less than or equal to 2 x upper limit of normal\n* Blood urea nitrogen (BUN) less than 2 x upper limit of normal\n* Creatinine less than 1.5 x upper limit of normal\n* Stable hemoglobin greater than or equal to 8.0 g\u002Fdl\n* Potassium between range of 3.0 to 5.5\n* Magnesium level between 1.6-2.6 mg\n\nExclusion Criteria:\n\n* Patients with the following cardiac diagnoses: ventricular tachycardia or fibrillation; Torsade des Pointes; clinically significant bradycardia; sinus node dysfunction; heart block; prolonged QTc interval (QTc \\> 450 milliseconds for males, QTc \\> 470 milliseconds for females); prior specific cardiovascular conditions of clinically significant valvular heart disease requiring medication, ischemic, or pulmonary heart disease; cardiomyopathy; history of heart failure\n* Patients who are receiving antiarrhythmic medications with action on repolarization times (with prolongation of the QTc interval such as amiodarone, disopyramide, dofetilide, flecainide, ibutilide, quinidine, sotalol, dronedarone etc.)\n* Patients who are receiving monoamine oxidase (MAO) inhibitors\n* Patients with a history of or active liver failure\n* Clinically significant electrolyte disorders including sodium \\\u003C 130 or \\> 145 and\u002For potassium \\\u003C 3.0 or \\> 5.5 and\u002For magnesium \\\u003C 1.6 or \\> 2.6\n* GI hemorrhage or obstruction experienced within the previous 6 weeks\n* Presence of a prolactinoma (prolactin-releasing pituitary tumor)\n* Pregnant or breast-feeding female (women of childbearing potential \\[WOCBP\\], defined as not post-menopausal for 12 months or without previous surgical sterilization, must have a negative urine pregnancy test within 30 days of the first administration of domperidone and must either commit to continued abstinence from heterosexual intercourse or use an effective method of birth control during the course of the study)\n* Known allergy to domperidone","16 Years",{"count":212,"type":20},200,[214],"PHASE3","This phase III trial studies how well domperidone works in treating patients with gastrointestinal disorders. Domperidone may help control chronic gastrointestinal disorders and their symptoms, such as pain, bloating, and nausea and vomiting, by stimulating contraction of the stomach to increase its ability to empty itself of food.",[217,218,219,220,27,221,222],"Digestive System Disorder","Dyspepsia","Esophagitis","Gastroesophageal Reflux Disease","Heartburn","Nausea and Vomiting","2026-04-10",{"date":193,"type":46},{"date":226,"type":46},"2012-10-23",{"date":228,"type":20},"2027-10-31",{"name":230,"class":53},"M.D. Anderson Cancer Center",{"id":232,"slug":233,"hasResults":12,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":237,"eligibilityCriteria":238,"healthyVolunteers":12,"sex":17,"minAge":239,"maxAge":240,"enrollmentInfo":241,"targetDuration":243,"studyType":22,"phases":4,"briefSummary":244,"conditions":245,"keywords":247,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":259},"100514653","gpcrc-pediatric-gastroparesis-registry-2-100514653","NCT05981300","GpCRC Pediatric Gastroparesis Registry 2","GpCRC Pediatric Gastroparesis Registry 2: Characterization and Clinical Course of Symptoms and Gastric Emptying in Pediatric, Adolescent, and Young Adult Participants With Symptoms of Gastroparesis","PGpR2","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form and assent, as age appropriate.\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* 8 to 25 years of age at the time of enrollment\n* Symptoms of Gp of at least 12 weeks duration: constellation of some combination of:\n\nnausea, vomiting, early satiety, postprandial fullness; symptoms sometimes may be accompanied by upper abdominal pain\n\n* Have undergone a gastric emptying scintigraphic study of solids using 4-hour Egg Beaters protocol (or equivalent generic liquid egg white meal) within the last 12 months who fall into one of the two categories:\n* Delayed gastric emptying-defined as an abnormal 2-hour (\\>60% retention) and\u002For 4- hour (\\>10% retention) result based on a 4-hour scintigraphic gastric emptying study\n* Gastric emptying that is not delayed but who have symptoms of Gp (designated in this study as GLS) or have previously participated in the Pediatric Gastroparesis Registry (PGpR) study\n* An etiology of either diabetic or idiopathic Gp or GLS\n\nExclusion Criteria:\n\n* Inability to comply with or complete the scintigraphic gastric emptying test (including allergy to eggs)\n* Pregnancy\n* Autism spectrum disorder, significant developmental delay, psychosis (because of inability to complete questionnaires)\n* Use of narcotic analgesics greater than three days per week.\n* Presence of conditions associated with GI mucosal disease (e.g., inflammatory bowel disease, known eosinophilic gastroenteritis or eosinophilic esophagitis, gastric ulcer, peptic ulcer, celiac disease)\n* Presence of any other condition that could case delayed gastric emptying\n* Gastrointestinal construction confirmed by upper endoscopy (EGD), upper gastrointestinal series (UGI), or abdominal CT\n* Primary neurological conditions that can cause nausea and vomiting such as increased intracranial pressure, space occupying or inflammatory\u002Finfectious legions\n* Acute or chronic renal failure (abnormal creatinine for age) and \u002For on hemodialysis or peritoneal dialysis\n* Acute liver failure\n* Advanced liver disease (features of portal hypertension)\n* Clinically significant congenital heart disease (i.e., vaginal injury during cardiac repair)\n* History of esophageal, gastric or bowel surgery.\n* Metabolic disease including mitochondrial disease and inborn errors of metabolism\n* Chronic lung disease (including cystic fibrosis)\n* A serious chronic medical condition (e.g., inflammatory bowel disease)\n* Use of medications that can affect motility during the gastric emptying study\n* Any other condition, which in the option of the investigator, could explain the symptoms or could interfere with study requirements.","8 Years","25 Years",{"count":242,"type":20},216,"3 Years","The objective of the Pediatric Gastroparesis Registry 2 is to create a national prospective registry of children, adolescents, and young adults with gastroparesis and gastroparesis-like syndrome (symptoms of gastroparesis but normal gastric emptying).",[27,246],"Gastroparesis-like Syndrome",[248,249],"Functional Disorder of Gastrointestinal Tract","Gastro-Intestinal Disorder","2026-03-30",{"date":252,"type":46},"2026-04-03",{"date":254,"type":46},"2024-12-18",{"date":256,"type":20},"2027-04-30",{"name":258,"class":53},"Johns Hopkins Bloomberg School of Public Health",6,{"id":261,"slug":262,"hasResults":12,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":266,"eligibilityCriteria":267,"healthyVolunteers":12,"sex":17,"minAge":88,"maxAge":268,"enrollmentInfo":269,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":271,"conditions":272,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":276,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":280,"locationsCount":259},"100504322","gastroparesis-registry-4-100504322","NCT05846802","Gastroparesis Registry 4","Gastroparesis Registry 4 (GpR4): Improving the Understanding of Gastroparesis and Functional Dyspepsia","GpR4","Inclusion Criteria:\n\n* Age at least 18 years at initial screening visit\n* Symptoms of Gp and\u002For FD of at least 12-weeks duration with varying degrees of nausea, vomiting, early satiety, postprandial fullness, abdominal pain, abdominal burning. Thus, patients can enter the GpR4 registry primarily with abdominal pain suggesting FD-Epigastric Pain Syndrome.\n* Successful completion of gastric emptying scintigraphy of solids using the 4-hour Egg Beaters® protocol (or equivalent generic liquid egg white meal) within the last 9 months\n* Negative upper endoscopy or upper radiographic GI series within 5 years of registration\n\nExclusion Criteria:\n\n* Use of narcotic analgesics greater than three days per week\n* Presence of other conditions that could explain the patient's symptoms such as:\n* Pyloric or intestinal obstruction as evidenced by EGD, UGI, or Abdominal CT\n* Active inflammatory bowel disease\n* Known eosinophilic gastroenteritis or eosinophilic esophagitis\n* Primary neurological conditions that can cause nausea and vomiting such as increased intracranial pressure, space occupying or inflammatory\u002Finfectious lesions\n* Acute or chronic renal failure (serum creatinine \\>3 mg\u002FdL) and\u002For on hemodialysis or peritoneal dialysis\n* Acute liver failure or advanced liver disease (Child's B or C; a Child-Pugh-Turcotte (CPT) score of ≥7)\n* Pancreatic disorder if present on pancreatic imaging or pancreatic function testing\n* Prior gastric surgery including total or subtotal (near complete) gastric resection, esophagectomy, gastrojejunostomy, gastric bypass, gastric sleeve, pyloroplasty, pyloromyotomy, or any fundoplication (Nissen, Tor)\n* Any other condition, which in the opinion of the investigator, could explain the symptoms or interfere with study requirements\n* Females who are pregnant. A urine pregnancy test is routinely obtained on all females immediately prior to gastric emptying procedures.\n* Inability to comply with or complete the gastric emptying scintigraphy test (including allergy to eggs)\n* Inability to obtain informed consent","85 Years",{"count":270,"type":20},250,"The Gastroparesis Registry 4 (GpR4) is an observational study of patients with symptoms of gastroparesis (Gp) and functional dyspepsia (FD) with either delayed or normal gastric emptying. To better understand these disorders, this registry will capture demographic, clinical, physiological, questionnaire, and patient outcome data to characterize the patients and their clinical course. Participants will complete several questionnaires, complete a nutrient drink test and have a gastric emptying study.",[27,273,274,275,248,249],"Gastroparesis Nondiabetic","Gastroparesis Due to Diabetes Mellitus Type I","Gastroparesis Due to Diabetes Mellitus Type II",{"date":252,"type":46},{"date":278,"type":46},"2024-09-20",{"date":256,"type":20},{"name":258,"class":53},{"id":282,"slug":283,"hasResults":12,"nctId":284,"briefTitle":285,"officialTitle":285,"acronym":286,"eligibilityCriteria":287,"healthyVolunteers":62,"sex":17,"minAge":88,"maxAge":268,"enrollmentInfo":288,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":289,"conditions":290,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":293,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":298,"locationsCount":299},"100413256","pyloric-sphincter-abnormalities-in-patients-with-gastroparesis-symptoms-100413256","NCT04661215","Pyloric Sphincter Abnormalities in Patients With Gastroparesis Symptoms","PSAGS","Inclusion Criteria FOR SYMPTOMATIC PARTICIPANTS:\n\n1. Provision of signed and dated informed consent form.\n2. Stated willingness to comply with all study procedures and availability for the duration of the study.\n3. Male or female, aged 18-85\n4. Symptoms of gastroparesis, either diabetic or idiopathic etiology\n5. Symptoms of gastroparesis with minimum Gastroparesis Cardinal Symptom Index (GCSI) score of 2.0\n6. Individual will have had a prior 4-hour gastric emptying scintigraphy test performed for clinical evaluation within the last 6 months. This gastric emptying test would be done for clinical evaluation and is not part of the research study. From these participants with gastroparesis symptoms, we will include those with delayed gastric emptying as well as those with normal gastric emptying.\n7. Participant must not initiate any new treatments until completion of the study procedures.\n8. Willingness to:\n\n   1. Stop histamine 2 antagonists, prokinetics (e.g., metoclopramide, erythromycin, domperidone, prucalopride), narcotics, anticholinergics, constipation medications (over the counter laxatives, isotonic polyethylene glycol (PEG) electrolyte preparations (e.g. MiraLax), prescription laxatives (e.g. lubiprostone), proton pump inhibitors, cannabinoids, and cannabidiol (CBD) for 3 days prior to each visit;\n   2. Abstain from food and water after midnight (at least for 8 hours) before the start of each visit until after the visit.\n\nINCLUSION CRITERIA FOR CONTROL PARTICIPANTS\n\n1. Provision of signed and dated informed consent form\n2. Male or female, aged 18 or older\n3. Undergoing an upper endoscopy for their clinical evaluation of diarrhea, GI bleed, or iron-deficiency anemia, or evaluation for bariatric surgery.\n4. Do not have upper GI symptoms greater than 1 as assessed by the Gastroparesis Cardinal Symptom Index (GCSI) of PAGI-SYM questionnaire.\n\nEXCLUSION CRITERIA:\n\n1. Prior gut lumen surgery on the esophagus or the stomach, including Nissen fundoplication.\n2. Prior surgery on the pylorus (G-POEM, surgical pyloroplasty, surgical pyloromyotomy)\n3. Known history of achalasia or esophageal stricture\n4. Known history of physiological or mechanical GI obstruction\n5. Abnormalities seen on a prior upper endoscopy placing patient at increased risk:\n\n   * Ulcer of the esophagus, stomach, or duodenum\n   * Esophageal varices\n6. Individuals at risk for prolonging the endoscopy procedure: severe chronic pulmonary disease, severe food retention in the stomach on endoscopy.\n7. Presence of significant gastric or duodenal pathology that could be expected to cause dysmotility (e.g. significant inflammation, infiltrate disorders etc)\n8. Individuals with a history of other chronic disease potentially causative of gastrointestinal symptom\n9. Acute or chronic renal insufficiency\n10. Current eating disorders\n11. Females who are pregnant. A urine pregnancy test is routinely obtained on all females immediately prior to endoscopic procedures.\n12. Individuals with contraindications for endoscopy, including bleeding abnormalities\n13. Allergy to eggs preventing sedation with propofol and\u002For gastric emptying test\n14. Significant dysphagia\n15. Prior inflammatory bowel disease, Crohn's\n16. History of any esophageal\u002Fgastric\u002Fpyloric injection of botulinum toxin\n17. Patients on daily opioid use or \\>3 day\u002Fweek use\n18. Use of glucagon-like peptide 1 (GLP1) receptor agonists or Sodium-Glucose Transport Protein 2 (SGLT2); Gastric inhibitory polypeptide (GIP)- glucagon-like peptide (GLP) combo",{"count":115,"type":20},"The overall objective of this study is to determine if there are pyloric sphincter abnormalities in patients with gastroparesis symptoms and determine how prevalent these abnormalities are using tests to assess the pyloric sphincter - endoluminal functional luminal imaging probe (Endoflip™), water load satiety testing (WLST), and high-resolution cutaneous electrogastrography (HR-EGG) using Gastric Alimetry™ System.",[27,291,292],"Idiopathic Gastric Motility Disorder","Diabetic Gastroparesis",{"date":252,"type":46},{"date":295,"type":46},"2026-01-13",{"date":297,"type":20},"2027-04-15",{"name":258,"class":53},5,{"id":301,"slug":302,"hasResults":12,"nctId":303,"briefTitle":304,"officialTitle":305,"acronym":306,"eligibilityCriteria":307,"healthyVolunteers":12,"sex":17,"minAge":88,"maxAge":308,"enrollmentInfo":309,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":311,"conditions":312,"keywords":315,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":329,"startDateStruct":331,"completionDateStruct":333,"leadSponsor":335,"locationsCount":106},"100456887","study-of-gastric-motility-in-eosinophilic-gastritis-100456887","NCT05229432","Study of Gastric Motility in Eosinophilic Gastritis","Pilot Assessment to Find Evidence of Gastric Motility Abnormalities in Eosinophilic Gastric Disorders","OAT-FEED","Inclusion Criteria:\n\n* Eosinophilic gastritis (EG) defined as at least one endoscopy with histopathologic evidence of ≥ 30 eosinophils in 5 or more high powered fields (hpf's) with associated symptoms of EG.\n* Patient reported symptoms starting at least one year or more prior to screening consistent with a diagnosis of EG: nausea, vomiting, early satiety, abdominal pain\u002Fbloating, regurgitation, diarrhea.\n* Symptoms suggestive of a possible gastric motility disorder during the 60 days prior to screening including: nausea, vomiting, early satiety, post-prandial feeling of fullness or bloating.\n* Tolerance and willingness to consume the oatmeal meal in this study.\n\nExclusion Criteria:\n\n* Diagnosis of eosinophilic enteritis.\n* Inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis).\n* Known disorders associated with eosinophilic gastrointestinal (GI) diseases (e.g., D 816 V Kit+ systemic mastocytosis, Marfan syndrome or Loey's Dietz Syndrome).\n* Known inflammatory or autoimmune disorders associated with gastric dysmotility such as systemic sclerosis, lupus or eosinophilic fasciitis.\n* Uncontrolled diabetes or known diabetic complications of gastroparesis, neuropathy or nephropathy.\n* Taking opioid agents in the 2 weeks prior to screening and throughout the study.\n* History of strictures in the small bowel or stomach (e.g., pyloric stenosis) or gastric surgeries or procedures such as pyloromyotomy, pyloric dilation, pyloric resection, vagotomy, bariatric surgery or post-Nissen fundoplication or antrectomy with Billroth I, Billroth II or Roux-en-Y gastrojejunostomy.\n* Past or current medical problems or findings such as: advanced liver disease (Child's B or C), acute or chronic renal disease (serum creatinine \\> 3 mg\u002FdL), neurologic disease (e.g., dysautonomia), achalasia and adrenal insufficiency.","59 Years",{"count":310,"type":20},30,"Purpose:\n\nThe study is a cross-sectional observational study designed to determine if eosinophilic gastritis (EG) results in gastric motility impairment.\n\nHypothesis:\n\nGastric dysfunction occurs in the natural history of EG but is underdiagnosed due, in part, to contraindications to the use of the standard meals used in gastric emptying studies.",[313,27,314],"Eosinophilic Gastritis","Gastric Motility Disorder",[316,317,318,319,320,321,322,323,324,325,326,327],"Gastritis","Eosinophilic Gastrointestinal Disorders","Gastric Dysfunction","Gastric Dysmotility","Eosinophils","Eosinophilia","Eosinophilic Disorders","Digestive System Diseases","Immune System Diseases","Stomach Diseases","Gastric Emptying Scintigraphy","Endoscopy","2026-03-26",{"date":330,"type":46},"2026-03-31",{"date":332,"type":46},"2023-01-25",{"date":334,"type":20},"2026-12-01",{"name":336,"class":53},"Children's Hospital Medical Center, Cincinnati",{"id":338,"slug":339,"hasResults":12,"nctId":340,"briefTitle":341,"officialTitle":342,"acronym":4,"eligibilityCriteria":343,"healthyVolunteers":12,"sex":17,"minAge":88,"maxAge":4,"enrollmentInfo":344,"targetDuration":346,"studyType":22,"phases":4,"briefSummary":347,"conditions":348,"keywords":350,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":361,"locationsCount":54},"100572850","disposable-endoscope-platform-in-third-space-endoscopic-procedures-100572850","NCT06738628","Disposable Endoscope Platform in Third Space Endoscopic Procedures","Pilot Prospective Trial to Demonstrate Efficacy, Feasibility, and Safety of a Disposable Endoscope Platform in Third Space Endoscopic Procedures","Inclusion Criteria:\n\n1. Patient is ≥ 18 years old.\n2. Patients can provide informed consent.\n3. Patient is referred for third space endoscopic procedure including e-POEM, g-POEM.\n\nExclusion Criteria:\n\n1. Patient is \\\u003C 18 years old.\n2. Patient refused and\u002For unable to provide consent.\n3. Patient is a pregnant woman.",{"count":345,"type":20},40,"4 Weeks","This is a prospective, single-arm unblinded study performed at a single tertiary center in the United States. All subjects will receive standard medical care and no experimental interventions are going to be performed. The procedures will be performed by Dr. Mohamed Othman, Dr. Salmaan Jawaid, Dr. Tara Keihanian, and Dr. Fares Ayoub. All patients undergoing third space endoscopic procedures including e-POEM and g-POEM, meeting study inclusion criteria will be screened by study coordinators for preliminary eligibility and those who meet the inclusion criteria will be approached individually for further discussion about the study and obtaining informed consent.\n\nThe goal of this prospective, pilot trial is to demonstrate the efficacy, feasibility, safety, and clinical outcomes of third space endoscopic procedures completed using a disposable endoscope platform.",[349,27],"Achalasia",[351,352,353],"Per-Oral Endoscopic Myotomy","Gastric Per-Oral Endoscopic Myotomy","Disposable Endoscope","2026-03-20",{"date":356,"type":46},"2026-03-24",{"date":358,"type":20},"2026-05-30",{"date":360,"type":20},"2027-03-31",{"name":362,"class":53},"Baylor College of Medicine",{"id":364,"slug":365,"hasResults":12,"nctId":366,"briefTitle":367,"officialTitle":367,"acronym":4,"eligibilityCriteria":368,"healthyVolunteers":12,"sex":17,"minAge":369,"maxAge":370,"enrollmentInfo":371,"targetDuration":4,"studyType":116,"phases":373,"briefSummary":374,"conditions":375,"keywords":378,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":381,"startDateStruct":382,"completionDateStruct":384,"leadSponsor":386,"locationsCount":54},"100416202","compassionate-use-of-domperidone-for-refractory-gastroparesis-100416202","NCT04699591","Compassionate Use of Domperidone for Refractory Gastroparesis","Inclusion Criteria:\n\n1. Male or female\n2. Age 12 - 21\n3. Symptoms or manifestations secondary to GERD (e.g., persistent esophagitis, heartburn, upper airway signs or symptoms or respiratory symptoms), gastrointestinal motility disorders such as nausea, vomiting, severe dyspepsia or severe chronic constipation that are refractory to standard therapy.\n4. Patients must have a comprehensive evaluation to eliminate other causes of their symptoms.\n5. Patient has signed informed consent for the administration of domperidone that informs the patient of potential adverse events including:\n\n   * increased prolactin levels\n   * extrapyramidal side effects\n   * breast changes\n   * Cardiac arrhythmias including QT prolongation\n   * There is a potential for increased risk of adverse events with the drugs and herbal supplements listed in the addendum (See Addendum on pages 24 and 25)\n   * The coordinator\u002Finvestigator will have a discussion with the family about the use of any of the medications and herbal supplements listed in the addendum to make sure they understand the increased risk of their use and the need to contact the investigators prior to using any of the listed medications and herbal supplements.\n\nExclusion Criteria:\n\n1. History of, or current, arrhythmias including ventricular tachycardia, ventricular fibrillation and Torsade des Pointes. Patients with minor forms of ectopy (PACs) are not necessarily excluded.\n2. Clinically significant bradycardia, sinus node dysfunction, or heart block. Prolonged Tc (QTc\\> 450 milliseconds for males, QTc\\>470 milliseconds for females).\n3. Clinically significant electrolyte disorders.\n4. Gastrointestinal hemorrhage or obstruction\n5. Presence of a prolactinoma (prolactin-releasing pituitary tumor).\n6. Pregnant or breast feeding female\n7. Known allergy to domperidone","12 Years","21 Years",{"count":372,"type":20},20,[118],"The purpose of this program is to allow the use of domperidone in children from 12 to 21 years of age with symptoms related to motility disorders and Gastroesophageal reflux disease (GERD) who have failed all the standard treatments for their condition.",[376,377,27],"GERD","Gastroesophageal Reflux",[379,380],"reflux","acid reflux",{"date":356,"type":46},{"date":383,"type":4},"2013-04",{"date":385,"type":20},"2035-12",{"name":387,"class":53},"Jose Cocjin",{"id":389,"slug":390,"hasResults":12,"nctId":391,"briefTitle":392,"officialTitle":393,"acronym":4,"eligibilityCriteria":394,"healthyVolunteers":12,"sex":17,"minAge":88,"maxAge":4,"enrollmentInfo":395,"targetDuration":396,"studyType":22,"phases":4,"briefSummary":397,"conditions":398,"keywords":401,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":405,"lastUpdatePostDateStruct":406,"startDateStruct":408,"completionDateStruct":410,"leadSponsor":412,"locationsCount":106},"100600955","development-and-validation-of-a-risk-prediction-model-for-gastric-retention-in-patients-undergoing-sedated-gastroscopy-100600955","NCT07104214","Development and Validation of a Risk Prediction Model for Gastric Retention in Patients Undergoing Sedated Gastroscopy","Development and Validation of a Risk Prediction Model for Gastric Retention in Patients Undergoing Sedated Gastroscopy: a Multicentre Prospective Cohort Study","Inclusion Criteria:\n\n* Age ≥18 years.\n* Patients scheduled for elective sedated gastroscopy or sedated gastro-colonoscopy.\n* Participant provides informed consent.\n\nExclusion Criteria:\n\n* Acute upper gastrointestinal bleeding (active hematemesis, melena, or confirmed UGIB within 24h).\n* Emergency endoscopic procedures\n* Known pregnancy or lactation\n* Subjects deemed ineligible by investigators",{"count":19,"type":20},"1 Day","Gastric retention not only compromises the quality of endoscopic examination but also significantly increases the risk of reflux and aspiration in sedated patients. Aspiration of gastric contents represents a critical anesthesia-related complication during the perioperative period, carrying substantial implications for anesthetic management. With the growing volume of sedated gastroscopy procedures, predicting gastric retention has become an urgent clinical priority. This prospective study aims to establish a standardized gastric residual volume (GRV) grading system to evaluate both the volume of retained gastric contents and its contributing factors in patients undergoing upper gastrointestinal endoscopy. We will systematically assess the impact of demographic characteristics, comorbidities, and medication history on gastric emptying function. This study will facilitate establishment of an endoscopy-based simplified assessment system for gastric retention.",[399,400,27],"Gastric Cancer Stage","Esophageal Cancer",[402,403,27,404],"Gastric retention","Impaired gastric motility","Delayed gastric emptying","2026-03-09",{"date":407,"type":46},"2026-03-11",{"date":409,"type":46},"2025-08-03",{"date":411,"type":20},"2026-05-31",{"name":413,"class":53},"Zhejiang University",{"id":415,"slug":416,"hasResults":12,"nctId":417,"briefTitle":418,"officialTitle":418,"acronym":4,"eligibilityCriteria":419,"healthyVolunteers":12,"sex":17,"minAge":88,"maxAge":4,"enrollmentInfo":420,"targetDuration":4,"studyType":116,"phases":421,"briefSummary":422,"conditions":423,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":424,"lastUpdatePostDateStruct":425,"startDateStruct":427,"completionDateStruct":429,"leadSponsor":431,"locationsCount":54},"100553972","the-use-of-body-surface-gastric-mapping-in-assessing-the-clinical-success-of-g-poem-100553972","NCT06493032","The Use of Body Surface Gastric Mapping in Assessing the Clinical Success of G-POEM","Inclusion Criteria:\n\n* • Patients clinically eligible for G-Poem at our center.\n\nExclusion Criteria:\n\n* • Pregnant or breast-feeding\n\n  * Patients with gastroparesis due to spinal cord injuries due to difficulties in conducting the BSGM. Of note, we rarely see gastroparesis in this context.\n  * Inability to perform BSGM: history of severe skin allergies or sensitivity to cosmetics or lotions; chronically damaged or vulnerable epigastric skin (fragile skin, wounds, inflammation); patients unable to remain in a relaxed reclined position for the test duration.\n  * Patients with abdominal drains or tubes",{"count":372,"type":20},[118],"The purpose of this study is to investigate whether or not the investigators can utilize Body Surface Gastric Mapping to determine who would best benefit to receive G-POEM procedure and how Body Surface Gastric Mapping can be utilized with patients who have gastroparesis symptoms. the investigators may also be able to find more ways how Body Surface Gastric Mapping testing can benefit patients with gastroparesis and\u002For G-POEM procedure.",[27],"2026-02-16",{"date":426,"type":46},"2026-02-18",{"date":428,"type":46},"2024-11-07",{"date":430,"type":20},"2026-06-01",{"name":52,"class":53},{"id":433,"slug":434,"hasResults":12,"nctId":435,"briefTitle":436,"officialTitle":437,"acronym":438,"eligibilityCriteria":439,"healthyVolunteers":62,"sex":17,"minAge":88,"maxAge":4,"enrollmentInfo":440,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":442,"conditions":443,"keywords":444,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":424,"lastUpdatePostDateStruct":448,"startDateStruct":449,"completionDateStruct":451,"leadSponsor":453,"locationsCount":54},"100395875","gastric-per-oral-endoscopic-myotomy-g-poem-for-the-treatment-of-gastroparesis-100395875","NCT04434781","Gastric Per-Oral Endoscopic Myotomy (G-POEM) for the Treatment of Gastroparesis","Gastric Per-Oral Endoscopic Myotomy (G-POEM) for the Treatment of Gastroparesis: A Database Repository","G-POEM","Inclusion Criteria:\n\n* 18 years of age\n* Referral for endoscopic treatment of Gastroparesis for symptom management\n\nExclusion Criteria:\n\n* \\\u003C 18 years of age\n* Absence of gastroparesis based on scintigraphy studies",{"count":441,"type":20},75,"Gastric Per-Oral Endoscopic Myotomy (G-POEM) is a procedure for the Treatment of Gastroparesis.",[27],[445,352,446,27,447],"GPOEM","Myotomy","g-poem",{"date":426,"type":46},{"date":450,"type":46},"2018-08-07",{"date":452,"type":20},"2026-08-15",{"name":52,"class":53},{"id":455,"slug":456,"hasResults":12,"nctId":457,"briefTitle":458,"officialTitle":459,"acronym":4,"eligibilityCriteria":460,"healthyVolunteers":62,"sex":17,"minAge":239,"maxAge":240,"enrollmentInfo":461,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":463,"conditions":464,"keywords":468,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":473,"startDateStruct":475,"completionDateStruct":477,"leadSponsor":479,"locationsCount":299},"100506885","bsgm-to-evaluate-patients-with-gi-symptoms-100506885","NCT05880199","BSGM to Evaluate Patients With GI Symptoms","Body Surface Gastric Mapping (BSGM) to Evaluate Patients With Gastrointestinal (GI) Symptoms","Inclusion Criteria for Cases\n\n1. Males or females age 8 to 25 years.\n2. Females ≥11 years of age or who have reached menarche must have a negative urine pregnancy test.\n3. Confirmed diagnosis of a Functional Gastrointestinal and\u002For Motility Disorder OR undergoing one of the following procedures as part of their clinical care at one of the participating centers:\n\n   1. HRVB\n   2. PENFS\n   3. ADM\n   4. Colonic Manometry\n   5. Pyloric Botox\n   6. Pyloric Dilation\n   7. Gastric Scintigraphy\n   8. GES\n   9. gammaCore\n4. Those with a body mass index of \\\u003C 35.\n5. Parental\u002Fguardian permission (informed consent) and if appropriate, child assent.\n\nExclusion Criteria for Cases\n\n1. History of skin allergies or a history of extreme sensitivity to cosmetics or lotions. Currently open wounds, abrasions, infected or inflamed abdominal skin. (Please note, majority of feeding tubes can be accommodated by the array placement.)\n2. Pregnant women.\n3. Those with any condition, where fasting is not recommended by a physician.\n4. Any allergies to foods that may be present in the standardized meal that cannot be accommodated with an acceptable substitute meal.\n5. Those with physical limitations, who are not able to maintain a relaxed reclined position for the study visit duration.\n6. Those with major developmental delay or cognitive impairment, who are not able to report their symptoms\u002Ffeelings in the questionnaires.\n7. Those with GI motility disorders that are limited in the esophagus, and the gastric mapping is restricted to capture relevant data based on the investigator's discretion.\n8. Parents\u002Fguardians or subjects who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures.\n\nInclusion Criteria for Controls\n\n1. Males or females age 8 to 25 years.\n2. Females ≥11 years of age or who have reached menarche must have a negative urine pregnancy test.\n3. Do not have an active Functional Gastrointestinal disorder (FGID) diagnosis and will not be undergoing any procedures outlined in the recruitment plan in the near future.\n4. Those with a body mass index of \\\u003C 35.\n5. Individuals may include siblings of those with FGIDs.\n6. Parental\u002Fguardian permission (informed consent) and if appropriate, child assent.\n\nExclusion Criteria for Controls\n\n1. History of skin allergies or a history of extreme sensitivity to cosmetics or lotions. Currently open wounds, abrasions, infected or inflamed abdominal skin.\n2. Pregnant women.\n3. Those with any condition, where fasting is not recommended by a physician.\n4. Allergies to foods that may be included in the standardized meal that cannot be accommodated with an acceptable substitute meal.\n5. Those with physical limitations, who are not able to maintain a relaxed reclined position for the study duration.\n6. Those with major developmental delay or cognitive impairment, who are not able to report their symptoms\u002Ffeelings in the questionnaires.\n7. Those with GI motility disorders that are limited in the esophagus, and the gastric mapping is restricted to capture relevant data based on the investigator's discretion.\n8. Parents\u002Fguardians or subjects who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures.",{"count":462,"type":20},685,"The goal of this observational study is to learn about gastric myoelectric activity in children with GI symptoms. The main question it aims to answer is which patterns or signals are associated with GI symptoms as measured by a body surface gastric mapping (BSGM) device. Participants will have their stomach activity recorded for up to 4 hours using the BSGM device and log real-time symptoms. Researchers will compare the recordings of healthy children and children with GI symptoms to define abnormal GI patterns.",[465,466,27,467],"Gastrointestinal Motility Disorders in Children","Functional Gastrointestinal Disorders","Dyspepsia and Other Specified Disorders of Function of Stomach",[469,470,471],"GI motility","gastroparesis","functional dyspepsia","2026-02-06",{"date":474,"type":46},"2026-02-10",{"date":476,"type":46},"2021-10-01",{"date":478,"type":20},"2028-06-30",{"name":480,"class":53},"Children's Hospital of Philadelphia",{"id":482,"slug":483,"hasResults":12,"nctId":484,"briefTitle":485,"officialTitle":485,"acronym":486,"eligibilityCriteria":487,"healthyVolunteers":12,"sex":17,"minAge":88,"maxAge":4,"enrollmentInfo":488,"targetDuration":490,"studyType":22,"phases":4,"briefSummary":491,"conditions":492,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":497,"startDateStruct":499,"completionDateStruct":500,"leadSponsor":502,"locationsCount":54},"100508791","prospective-evaluation-of-the-clinical-utility-of-peroral-endoscopic-myotomy-for-gastrointestinal-motility-disorders-100508791","NCT05905016","Prospective Evaluation of the Clinical Utility of Peroral Endoscopic Myotomy for Gastrointestinal Motility Disorders","POEM","Inclusion Criteria:\n\n1. Age 18 years or older.\n2. Scheduled to undergo POEM\n\nExclusion Criteria:\n\n1. Any contraindication to performing endoscopy.\n2. Participation in another research protocol that could interfere or influence the outcomes measures of the present study.",{"count":489,"type":20},600,"12 Months","This is prospective data recording study. All patients will receive standard medical care and no experimental interventions will be performed.",[349,493,27,494,495],"Esophageal Spasm, Diffuse","Swallowing Disorder","Zenker Diverticulum","2026-01-29",{"date":498,"type":46},"2026-02-02",{"date":476,"type":46},{"date":501,"type":20},"2027-04",{"name":503,"class":53},"AdventHealth",{"id":505,"slug":506,"hasResults":12,"nctId":507,"briefTitle":508,"officialTitle":509,"acronym":4,"eligibilityCriteria":510,"healthyVolunteers":62,"sex":17,"minAge":511,"maxAge":512,"enrollmentInfo":513,"targetDuration":515,"studyType":22,"phases":4,"briefSummary":516,"conditions":517,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":519,"lastUpdatePostDateStruct":520,"startDateStruct":522,"completionDateStruct":524,"leadSponsor":525,"locationsCount":54},"100560672","the-role-of-aat-after-abdominal-surgery-based-on-rws-100560672","NCT06580197","The Role of AAT After Abdominal Surgery Based on RWS","Application of Auricular Acupuncture Therapy Based on Real-World Studies After Abdominal Surgery","Inclusion Criteria:\n\n\\- 1) Age range: 40-70 years old (40 ≤ y ≤ 70), gender is not limited. 2) Accept abdominal surgeries including Whipple's surgery, pancreatectomy, and subtotal gastrectomy.\n\n3\\) The subjects\u002Fguardians are able to understand the purpose of the trial, demonstrate sufficient compliance with the trial protocol, and sign an informed consent form (ICF)\n\nExclusion Criteria:\n\n* 1\\) Severe postoperative complications such as heart disease, pulmonary embolism, cerebral infarction, abdominal infection, and abdominal bleeding; 2) Patients with organic changes such as adhesions and obstructions indicated by imaging examinations such as gastrointestinal imaging; 3) The patient has damage, redness, bleeding, infection, and other conditions in both ears that are not suitable for ear acupuncture treatment.\n\nInclusion and exclusion criteria for the health group\n\nInclusion Criteria:\n\n1. Age range: 40-70 years old (40 ≤ y ≤ 70), gender is not limited.\n2. No history of abdominal surgery or tumor, and no significant abnormalities were found through abdominal imaging examination.\n3. The subjects\u002Fguardians are able to understand the purpose of the trial, demonstrate sufficient compliance with the trial protocol, and sign an informed consent form (ICF).\n\nExclusion Criteria:\n\n1. Symptoms of digestive discomfort such as diarrhea, constipation, and vomiting have been present for the past 30 days.\n2. The patient has conditions such as damage, redness, bleeding, and infection in both ears that affect the assessment of ear acupoint information.","40 Years","70 Years",{"count":514,"type":20},159,"1 Month","Delayed gastric emptying (DGE) after surgery mainly occurs after gastrointestinal surgery A functional gastric emptying disorder, clinically characterized by weak or absent gastric peristalsis, gastric motility disorders, or gastric emptying Gastric retention, fullness, nausea and other uncomfortable symptoms caused by delay.This study is based on clinical diagnosis and treatment practice, observing, collecting, and analyzing Whipple surgery, pancreatectomy, and gastric cancer Perioperative data of subtotal resection surgery, mainly observing the diagnosis and treatment of ear acupoints in Whipple surgery, pancreatectomy, and subtotal gastrectomy.The application effect of DGE after resection surgery, exploring the diagnosis and treatment of ear acupoints in Whipple surgery, pancreatic body and tail resection surgery, and Diagnostic value of perioperative related diseases in abdominal surgery such as subtotal gastrectomy, and collection of health records.By comparing and analyzing the ear acupoint information of patients with abdominal tumors, we aim to explore the ear acupoints of the volunteers. The possible relationship between image and resistance specificity and common tumors in the abdominal cavity.",[518,27],"Acupuncture, Ear","2025-09-08",{"date":521,"type":46},"2025-09-15",{"date":523,"type":46},"2024-12-01",{"date":334,"type":20},{"name":526,"class":53},"Peking Union Medical College Hospital",{"id":528,"slug":529,"hasResults":12,"nctId":530,"briefTitle":531,"officialTitle":532,"acronym":4,"eligibilityCriteria":533,"healthyVolunteers":12,"sex":17,"minAge":88,"maxAge":512,"enrollmentInfo":4,"targetDuration":4,"studyType":534,"phases":4,"briefSummary":535,"conditions":536,"keywords":537,"overallStatus":550,"whyStopped":4,"lastUpdateSubmitDate":551,"lastUpdatePostDateStruct":552,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":554,"locationsCount":557},"100398963","single-patient-expanded-access-protocol-for-tradipitant-in-a-single-patient-with-gastroparesis-100398963","NCT04474990","Single-Patient Expanded Access Protocol for Tradipitant In A Single Patient With Gastroparesis","VP-VLY-686-3303: Single-Patient Expanded Access Protocol for Tradipitant In A Single Patient With Gastroparesis","Inclusion Criteria:\n\n* Identified subject who requested expanded access\n* Diagnosed with gastroparesis\n* Demonstrated delayed gastric emptying\n* Presence of moderate to severe nausea\n* Patient does not qualify for or does not have access to other clinical trials with tradipitant;\n\nExclusion Criteria:\n\n* Another active disorder or treatment which could explain or contribute to symptoms of gastroparesis\n* A positive test for drugs of abuse at the screening or evaluation visits;\n* Exposure to any investigational medication in the past 60 days other than tradipitant\n* Gastrectomy, fundoplication, vagotomy, pyloroplasty, bariatric surgery, or gastric stimulation device surgically implanted within the last year\n* Any other reason as determined by the Investigator which may lead to an unfavorable risk-benefit ratio to treatment;","EXPANDED_ACCESS","Primary Objective: To treat a single patient with gastroparesis who has requested expanded access with tradipitant",[27,292],[470,538,539,540,541,542,543,544,545,546,547,548,549],"idiopathic","diabetic","tradipitant","nausea","vomiting","stomach","motility","functional","NK-1 antagonist","neurokinin 1 receptor","substance p","expanded access","AVAILABLE","2025-08-18",{"date":553,"type":46},"2025-08-24",{"name":555,"class":556},"Vanda Pharmaceuticals","INDUSTRY",15,{"id":559,"slug":560,"hasResults":12,"nctId":561,"briefTitle":562,"officialTitle":563,"acronym":4,"eligibilityCriteria":564,"healthyVolunteers":12,"sex":17,"minAge":88,"maxAge":4,"enrollmentInfo":565,"targetDuration":567,"studyType":22,"phases":4,"briefSummary":568,"conditions":569,"keywords":572,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":575,"startDateStruct":577,"completionDateStruct":579,"leadSponsor":581,"locationsCount":54},"100566937","laparoscopic-implantation-of-a-gastric-pacemaker-in-the-treatment-of-gastroparesis-100566937","NCT06661668","Laparoscopic Implantation of a Gastric Pacemaker in the Treatment of Gastroparesis","Laparoscopic Implantation of a Gastric Pacemaker is a Low-complication Alternative for Gastroparesis","Inclusion Criteria:\n\n* Scintigraphically proven gastroparesis\n* Failed conservative therapy\n* Severe impairment of quality of life\n* Written informed consent\n* German language\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Prior gastric resection",{"count":566,"type":20},50,"5 Years","Gastroparesis is a burdensome condition that is caused by abnormal motor function of the stomach that results in delayed gastric emptying. It typically manifests with bloating, nausea, vomiting, abdominal pain, and even excessive weight loss and dehydration. The most common causes of gastroparesis are idiopathic, diabetic, medication-induced or iatrogenic (postsurgical) gastroparesis.\n\nImplantation of a gastric neurostimulation device is a surgical option to improve gastric emptying in patients with medication-refractory gastroparesis. Enterra® system is a gastric electrical stimulation that sends mild pulses through leads implanted in the stomach wall that stimulate gastric smooth muscles and nerves in order to improve symptoms and quality of life.\n\nAim of the investogators' registry trial is to evaluate the feasibility and efficacy of laparoscopic gastric pacemaker implantation for electrical stimulation (Enterra® system). Primary endpoints of the study are symptom severity, health-related quality of life, and frequency of hospitalization before and after pacemaker implantation, perioperative complication rate, and cost effectiveness.",[27,570,273,571],"Gastroparesis Postoperative","Gastroparesis With Diabetes Mellitus",[27,573],"Gastric pacemaker","2025-08-06",{"date":576,"type":46},"2025-08-12",{"date":578,"type":46},"2023-01-01",{"date":580,"type":20},"2026-12-31",{"name":582,"class":53},"Evangelic Hospital Kalk Cologne",{"id":584,"slug":585,"hasResults":12,"nctId":586,"briefTitle":587,"officialTitle":587,"acronym":588,"eligibilityCriteria":589,"healthyVolunteers":12,"sex":17,"minAge":369,"maxAge":64,"enrollmentInfo":590,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":592,"conditions":593,"keywords":596,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":598,"lastUpdatePostDateStruct":599,"startDateStruct":601,"completionDateStruct":603,"leadSponsor":605,"locationsCount":54},"100378536","ivig-for-drug-and-device-refractory-gastrointestinal-auto-immune-neuropathy-100378536","NCT04208828","IVIG for Drug and Device Refractory Gastrointestinal Auto-Immune Neuropathy","GAIN","Inclusion Criteria: Patient with otherwise refractory symptoms of gastrointestinal (GI) motor disorders.\n\n\\-\n\nExclusion Criteria: Inability to receive intravenous immunoglobulin.\n\n\\-",{"count":591,"type":20},400,"Patients with the symptoms of generalized GI dysmotility, including gastroparesis, are sometimes refractory to available medications, devices and other interventions\u002F Some of these patients have serologic and\u002For endo organ abnormalities and findings consistent with autoimmune neuropathies, primarily involving the GI tract. These disorders have been known as autoimmune gastrointestinal neuropathies (GAIN) or also as autoimmune gastrointestinal dysmotility (AGID), among other terms. Some patients respond to intravenous immunoglobulin (IVIG) and this study, which is an observational clinical series, documents the patients, their findings and standardized responses to therapy with IVIG.",[594,27,595],"Gastrointestinal Motility Disorder","Neuropathy",[27,71,39,597,595],"Abdominal Pain","2025-07-29",{"date":600,"type":46},"2025-08-01",{"date":602,"type":46},"2020-01-02",{"date":604,"type":20},"2028-01-02",{"name":137,"class":53},{"id":607,"slug":608,"hasResults":12,"nctId":609,"briefTitle":610,"officialTitle":611,"acronym":4,"eligibilityCriteria":612,"healthyVolunteers":12,"sex":17,"minAge":88,"maxAge":4,"enrollmentInfo":613,"targetDuration":4,"studyType":116,"phases":614,"briefSummary":615,"conditions":616,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":618,"lastUpdatePostDateStruct":619,"startDateStruct":621,"completionDateStruct":623,"leadSponsor":625,"locationsCount":54},"100415939","impact-of-per-oral-pyloromyotomy-pop-on-glycemic-control-in-diabetes-100415939","NCT04696159","Impact of Per Oral Pyloromyotomy (POP) on Glycemic Control in Diabetes","Impact of Endoscopic Per-Oral Pyloromyotomy (POP) on Glycemic Control in Gastroparesis Patients With Poorly Controlled Diabetes Mellitus","Inclusion Criteria:\n\n1. Patients 18 years of age and older\n2. Patients with gastroparesis with an average HbA1c\\> 7.5% over the past 3 months\n3. Patient that have a diagnosis of gastroparesis established by documented delayed gastric emptying by either a wireless motility capsule study or a nuclear gastric emptying study, with no evidence of gastric obstruction.\n4. Patients are able to complete all study requirements\n\nExclusion Criteria:\n\n1. Patients \\\u003C18 years of age\n2. Patients with gastroparesis with an average HbA1c\\\u003C 7.5% over the past 3 months\n3. Patients unable or refuse to complete the study requirements\n4. Patients who are unable or refuse to wear a CGM sensor\n5. Patients with insulin pumps\n6. Patients who already use a CGM",{"count":345,"type":20},[118],"This study will assess changes in glycemic control in 40 patients with diabetes who undergo per-oral pyloromyotomy (POP) for medically refractory gastroparesis.",[617,571,27],"Diabetes Mellitus","2025-07-21",{"date":620,"type":46},"2025-07-24",{"date":622,"type":46},"2023-01-04",{"date":624,"type":20},"2027-06",{"name":626,"class":53},"Matthew Allemang",{"id":628,"slug":629,"hasResults":12,"nctId":630,"briefTitle":631,"officialTitle":632,"acronym":4,"eligibilityCriteria":633,"healthyVolunteers":12,"sex":17,"minAge":88,"maxAge":4,"enrollmentInfo":634,"targetDuration":4,"studyType":116,"phases":636,"briefSummary":638,"conditions":639,"keywords":642,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":646,"lastUpdatePostDateStruct":647,"startDateStruct":649,"completionDateStruct":651,"leadSponsor":653,"locationsCount":54},"100565802","phase-1-tens-in-scleroderma-100565802","NCT06646913","TENS in Scleroderma","Transcutaneous Electrical Nerve Stimulation in Scleroderma","Inclusion Criteria:\n\n1. Classification of Systemic Sclerosis according to the 2013 American College of Rheumatology and European League against Rheumatism classification criteria.\n2. Age \\>= 18 years\n3. English speaking.\n4. Participants who report moderate to severe symptoms of distension\u002Fbloating on UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract Instrument 2.0\n5. Stable GI specific therapy including prokinetics over the last 4 weeks.\n\nExclusion Criteria:\n\n1. Pregnancy, or currently lactating.\n2. A history of major abdominal surgery (other than cholecystectomy, appendectomy, or deemed as non-major by the investigators)\n3. Unrelated active disorder which may involve abdominal pain, such as inflammatory bowel disease, diabetes or unstable thyroid disease.\n4. Known allergy to adhesive ECG electrodes.\n5. Known contraindications to TEA (e.g., cardiac pacemaker, epilepsy)",{"count":635,"type":20},16,[637],"PHASE1","The goal of this pilot study is to assess the acceptability of the transcutaneous electrical acustimulation (TEA) device in treating Scleroderma-related gastroparesis. The main objective is:\n\nTo evaluate the acceptability of TEA as an intervention for alleviating symptoms of distension and bloating in individuals diagnosed with Scleroderma.\n\nParticipants will be provided with the TEA devices that will be applied to the skin for a total of 45 minutes twice daily after meals. Participants will be asked to fill out both daily diaries and biweekly questionnaires to assess for improvement in the gastroparesis symptoms. Participants will also be asked to complete the daily diaries in addition weekly questionnaires during a 4 week post-treatment follow-up period.",[640,27,641],"Scleroderma","Systemic Sclerosis (SSc)",[643,640,27,644,645],"TENS","Pilot Study","Systemic Sclerosis","2025-06-30",{"date":648,"type":46},"2025-07-03",{"date":650,"type":46},"2024-10-01",{"date":652,"type":20},"2026-05",{"name":654,"class":53},"University of Michigan"]